Short Interest in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Grows By 41.1%

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXPGet Free Report) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 343,700 shares, a growth of 41.1% from the January 15th total of 243,600 shares. Approximately 3.0% of the company’s stock are short sold. Based on an average daily trading volume, of 246,100 shares, the days-to-cover ratio is presently 1.4 days.

Analysts Set New Price Targets

Separately, HC Wainwright upped their price target on shares of Acurx Pharmaceuticals from $13.00 to $14.00 and gave the company a “buy” rating in a report on Friday, December 15th.

Get Our Latest Report on ACXP

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Sigma Planning Corp acquired a new position in Acurx Pharmaceuticals during the fourth quarter worth $38,000. One68 Global Capital LLC acquired a new position in Acurx Pharmaceuticals during the second quarter worth $35,000. BlackRock Inc. boosted its holdings in Acurx Pharmaceuticals by 149.8% during the first quarter. BlackRock Inc. now owns 16,699 shares of the company’s stock worth $55,000 after purchasing an additional 10,014 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its holdings in Acurx Pharmaceuticals by 37.5% during the second quarter. Osaic Holdings Inc. now owns 22,000 shares of the company’s stock worth $58,000 after purchasing an additional 6,000 shares during the last quarter. Institutional investors and hedge funds own 11.28% of the company’s stock.

Acurx Pharmaceuticals Stock Up 4.2 %

Acurx Pharmaceuticals stock opened at $2.99 on Tuesday. The stock has a market capitalization of $41.17 million, a PE ratio of -2.85 and a beta of -1.83. Acurx Pharmaceuticals has a twelve month low of $1.17 and a twelve month high of $8.82. The company has a 50 day moving average of $3.78 and a 200-day moving average of $3.14.

Acurx Pharmaceuticals (NASDAQ:ACXPGet Free Report) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.04. Equities analysts anticipate that Acurx Pharmaceuticals will post -1.03 EPS for the current fiscal year.

About Acurx Pharmaceuticals

(Get Free Report)

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.

Featured Stories

Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.